MARKET

PLRX

PLRX

Pliant Therapeutics, Inc.
NASDAQ
1.155
+0.035
+3.13%
After Hours: 1.155 0 0.00% 19:30 08/21 EDT
OPEN
1.120
PREV CLOSE
1.120
HIGH
1.170
LOW
1.120
VOLUME
504.69K
TURNOVER
--
52 WEEK HIGH
1.950
52 WEEK LOW
1.020
MARKET CAP
71.52M
P/E (TTM)
-0.7712
1D
5D
1M
3M
1Y
5Y
1D
Here's Why We're Watching Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation
Simply Wall St · 3d ago
Pliant Therapeutics receives Fast Track designation from FDA for PLN-101095
TipRanks · 4d ago
Pliant Therapeutics Receives Fast Track Designation From FDA For PLN-101095 In Combination With Pembrolizumab For Potential Treatment Of Solid Tumors
Benzinga · 4d ago
Analysts Offer Insights on Healthcare Companies: Quoin Pharmaceuticals (QNRX) and Pliant Therapeutics (PLRX)
TipRanks · 4d ago
Weekly Report: what happened at PLRX last week (0810-0814)?
Weekly Report · 5d ago
Canaccord Genuity Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)
TipRanks · 08/13 11:18
Oppenheimer Sticks to Their Hold Rating for Pliant Therapeutics (PLRX)
TipRanks · 08/13 07:25
RBC Capital Sticks to Their Hold Rating for Pliant Therapeutics (PLRX)
TipRanks · 08/12 11:07
More
About PLRX
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.

Webull offers Pliant Therapeutics Inc stock information, including NASDAQ: PLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLRX stock methods without spending real money on the virtual paper trading platform.